Posted in Antibodies, Assay Kits, Biology Cells, cDNA, Clia Kits, DNA Templates, DNA Testing, Elisa Kits, Enzymes, Equipments, Exosomes, Gels, Isotypes, Reagents, Recombinant Proteins, Ria Kits, RNA
The Relationship of Cholangiocarcinoma with Human Immunodeficiency Virus Cholangiopathy and Cytomegalovirus Infection
The human immunodeficiency virus (HIV) is a disease worldwide with the increasing number of cases globally. Initially, HIV colliaiopati was often observed among these patients but has become rare after three decades due to the availability of new care choices and strong antiretroviral drugs. As a result, the incident now suggests drug resistance or the development of the disease. The relationship between Cholaghiocarcinoma and HIV is still unclear. We report cases of patients with high-grade dysplasia from Choledochus ducts and uncontrolled diseases treated with strong antivirus agents and dilated bile tract.
Learning points: HIV Choligiopathy must be remembered in HIV-positive patients even if they receive combination (train) antiretroviral therapy; Endoscopy Retrograde Choliaiopancreatography can provide symptomatic assistance. After HIV Chorangiopathy is detected, follow-up for Cholangiocarcinoma is needed. Corrected infections can cause choliaiocarcinoma in HIV-positive patients.
The decrease in the incidence of acute rejection without increasing the incidence of cytomegalovirus (CMV) infection in recipients of kidney transplants that accept the anti-thymocyte globulin (RATG) rabbit without prophylactic CMV
Induction therapy with the anti-thymocyte globulin (RATG) rabbit in recipients of low-risk ktridal transplants (KTR) remains controversial, given the increased risk of cytomegalovirus (CMV) infection. This natural experiment compares the clinical results of 12 months in low-risk KTR without CMV prophylaxis (Jan / 3/13-Sep / 16/15) accepting without induction or a single dose of 3mg / kg. We use logistic regression to characterize the pending graft function (DGF), negative binomials to characterize the length of hospitalization of hospitals (LOS) and Cox regression to characterize acute rejection (AR), CMV infection, mistrident of grafting, death and readmission.
The recipient received 3mg / kg Ratg had a risk of 81% lower than AR (AHR 0.14 0.190.25, p <0.001) but there was no increase in hospital admission due to infection (0.911.21, p = 0.5). There is no relationship between 3 mg / kg infection / CMV disease (AHR 0.86 1,101.40, p = 0.5), even when analysis is grouped based on the positive CMV serostatatus (AHR 0.94 1.25 1.65, p = 0, 15) and negative (AHR 0.28 0.57 1.16, p = 0.1). There is no relationship between 3MG / kg Ratg and mortality (AHR 0.51 1,253.08, p = 0.6), loss of grafts (AHR 0.34 0.731.55, p = 0.4). Among the low-risk ktr that does not accept the pharmacological prophylaxis of CMV, induction of 3mg / kg Ratg is associated with a significant reduction in the incidence of AR without an increased risk of CMV infection, regardless of the pre-transplant receiver CMV serostatus.
Lesions such as Degos as a skin manifestation of Cytomegalovirus infection: rare and serious complications in patients with drug induced hypersensitivity syndrome
Cytomegalovirus causes a myriad of clinical features, potentially influencing any organ system, significantly increases morbidity and even mortality. Vascular endothelial cell infections by CyTomeGalovirus have been involved in the development of Vasculopathy, perhaps accounting for clinical relations between Cytomegalovirus and vascular thrombosis. Unlike the involvement of visceral organs, cytomegalovirus skin manifestations varies and are rarely explained. Papulosis of malignant atrophy, which is commonly known as a Degos disease, is an unusual arteriopathic ship with a patognomonic clinical appearance from the middle porcelain-white papules surrounded by erythema Telangiectatic.
Like the arterial occlusive process, Degos may be idiopathic or secondary to autoimmune disorders or viral infections. All in all, presentations such as Degos related to Cytomegalovirus have never been explained. This report illustrates cases where disseminated cytomegalovirus disease is developed 4 weeks after the emergence of hypersensitivity syndrome induced by drugs with skin lesions such as prominent degos. Our case highlights a rare example of lesions such as Degos that occur because of cytomegalovirus disease and emphasizes the importance of early recognition of skin eruption characteristics as a diagnostic instrument that leads to the management of this life-threatening infection.
Cytomegalovirus pancreatitis in immunocompetent patients
Cytomegalovirus (CMV) is a DNA virus whose double strand, which infects most of the adult population. In immunocompetent patients, usually asymptomatic or manifest as symptoms of mild flu and self-limit, while in immunocompromised patients, CMV can cause significant disease. Here we report cases of unusual CMV pancreatitis in the 75-year-old woman’s immunocompetent. Patients develop severe significant pancreatic necrosis that failed non-operative management, and ultimately underwent the Pancreatic Necrosectomy. Then, he developed three spontaneous gastric perforations.

The first two perforations were managed operatively, but after the third perforation family decided not to undergo other operations. The diagnosis of CMV pancreatitis is based on pancreatic histopathology and confirms with a rapid response to Ganciclovir. The patient immediately began at Ganciclovir Intravenous (IV) which resulted in clinical recovery and he remained without symptoms of more than one year post op. This is a rare case of CMV pancreatitis with gastric perforation in immunocompetent patients. The level of suspicion is high and the right maintenance is important for such a clinical scenario.
Microvascular and structural abnormalities extralesional in cytomegalovirus retinitis
To evaluate extraesional microvascular and structural changes from the macula using Optical Coherence Tomography Angiography (Octa) and Structural October in the Citomegalovirus Retinitis (CMVR). A CMVR patient observational study was conducted. Complete ophthalmic examination, serial color fundus fundus, structural October and Octa are carried out at the beginning and follow-up visits up to 12 months. The structural OCT was analyzed to evaluate the macular area inside, bordering and exceed CMVR lesions.
Plexus extraledional retina capillaries from maculas are evaluated with October angiography and compared to fellow eyes that are not affected. Thirteen eyes from 13 registered patients. On the basis, the macular area without CMVR lesions showed a decrease in ship density (VD) of both superficial (p = 0,0002) and inside (p <0.0001) the retinal capillary plexus in the eye with CMVR compared to the area of ​​the macular not affected by fellow eyes that are not affected. The decrease in VD survives through the follow-up period of up to 12 months after adjusting the degree of vitreous fog.
TTC39B Antibody, HRP conjugated |
1-CSB-PA713348LB01HU |
Cusabio |
|
|
|
Description: A polyclonal antibody against TTC39B. Recognizes TTC39B from Human. This antibody is HRP conjugated. Tested in the following application: ELISA |
TTC39B Antibody, FITC conjugated |
1-CSB-PA713348LC01HU |
Cusabio |
|
|
|
Description: A polyclonal antibody against TTC39B. Recognizes TTC39B from Human. This antibody is FITC conjugated. Tested in the following application: ELISA |
TTC39B Antibody, Biotin conjugated |
1-CSB-PA713348LD01HU |
Cusabio |
|
|
|
Description: A polyclonal antibody against TTC39B. Recognizes TTC39B from Human. This antibody is Biotin conjugated. Tested in the following application: ELISA |
TTC39B Recombinant Protein (Rat) |
RP235163 |
ABM |
100 ug |
Ask for price |
TTC39B Recombinant Protein (Human) |
RP033328 |
ABM |
100 ug |
Ask for price |
TTC39B Recombinant Protein (Mouse) |
RP182057 |
ABM |
100 ug |
Ask for price |
Rat TTC39B shRNA Plasmid |
20-abx988909 |
Abbexa |
|
|
|
Mouse TTC39B shRNA Plasmid |
20-abx977074 |
Abbexa |
|
|
|
Human TTC39B shRNA Plasmid |
20-abx965852 |
Abbexa |
|
|
|
Ttc39b ORF Vector (Rat) (pORF) |
ORF078389 |
ABM |
1.0 ug DNA |
EUR 506 |
TTC39B ORF Vector (Human) (pORF) |
ORF011110 |
ABM |
1.0 ug DNA |
EUR 95 |
Ttc39b ORF Vector (Mouse) (pORF) |
ORF060687 |
ABM |
1.0 ug DNA |
EUR 506 |
Polyclonal TTC39B Antibody (C-term) |
APR03519G |
Leading Biology |
0.1ml |
EUR 484 |
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human TTC39B (C-term). This antibody is tested and proven to work in the following applications: |
Ttc39b sgRNA CRISPR Lentivector set (Mouse) |
K4952201 |
ABM |
3 x 1.0 ug |
EUR 339 |
Ttc39b sgRNA CRISPR Lentivector set (Rat) |
K6591501 |
ABM |
3 x 1.0 ug |
EUR 339 |
TTC39B sgRNA CRISPR Lentivector set (Human) |
K2551101 |
ABM |
3 x 1.0 ug |
EUR 339 |
Tetratricopeptide Repeat Protein 39B (TTC39B) Antibody |
abx026040-400ul |
Abbexa |
400 ul |
EUR 523 |
|
Tetratricopeptide Repeat Protein 39B (TTC39B) Antibody |
abx026040-80l |
Abbexa |
80 µl |
EUR 286 |
|
Tetratricopeptide Repeat Protein 39B (TTC39B) Antibody |
abx145789-100ug |
Abbexa |
100 ug |
EUR 391 |
|
Tetratricopeptide Repeat Protein 39B (TTC39B) Antibody |
abx239086-100ug |
Abbexa |
100 ug |
EUR 509 |
|
HNRRabbit pAb Rabbit pAb |
A17497-200ul |
Abclonal |
200 ul |
EUR 459 |
HNRRabbit pAb Rabbit pAb |
A17497-20ul |
Abclonal |
20 ul |
EUR 183 |
HNRRabbit pAb Rabbit pAb |
A17497-100ul |
Abclonal |
100 ul |
EUR 308 |
HNRRabbit pAb Rabbit pAb |
A17497-50ul |
Abclonal |
50 ul |
EUR 223 |
Rabbit pAbPC4 Rabbit pAb |
A5948-100ul |
Abclonal |
100 ul |
EUR 308 |
Rabbit pAbPC4 Rabbit pAb |
A5948-200ul |
Abclonal |
200 ul |
EUR 459 |
Rabbit pAbPC4 Rabbit pAb |
A5948-20ul |
Abclonal |
20 ul |
EUR 183 |
Rabbit pAbPC4 Rabbit pAb |
A5948-50ul |
Abclonal |
50 ul |
EUR 223 |
Rabbit pAbPN1 Rabbit pAb |
A6041-100ul |
Abclonal |
100 ul |
EUR 308 |
Rabbit pAbPN1 Rabbit pAb |
A6041-200ul |
Abclonal |
200 ul |
EUR 459 |
Rabbit pAbPN1 Rabbit pAb |
A6041-20ul |
Abclonal |
20 ul |
EUR 183 |
Rabbit pAbPN1 Rabbit pAb |
A6041-50ul |
Abclonal |
50 ul |
EUR 223 |
Rabbit pAbPC3 Rabbit pAb |
A18370-100ul |
Abclonal |
100 ul |
EUR 308 |
Rabbit pAbPC3 Rabbit pAb |
A18370-200ul |
Abclonal |
200 ul |
EUR 459 |
Rabbit pAbPC3 Rabbit pAb |
A18370-20ul |
Abclonal |
20 ul |
EUR 183 |
Rabbit pAbPC3 Rabbit pAb |
A18370-50ul |
Abclonal |
50 ul |
EUR 223 |
Rabbit pAbPC1 Rabbit pAb |
A14872-100ul |
Abclonal |
100 ul |
EUR 308 |
Rabbit pAbPC1 Rabbit pAb |
A14872-200ul |
Abclonal |
200 ul |
EUR 459 |
Rabbit pAbPC1 Rabbit pAb |
A14872-20ul |
Abclonal |
20 ul |
EUR 183 |
Rabbit pAbPC1 Rabbit pAb |
A14872-50ul |
Abclonal |
50 ul |
EUR 223 |
Rabbit pAbPC5 Rabbit pAb |
A9997-100ul |
Abclonal |
100 ul |
EUR 308 |
Rabbit pAbPC5 Rabbit pAb |
A9997-200ul |
Abclonal |
200 ul |
EUR 459 |
Rabbit pAbPC5 Rabbit pAb |
A9997-20ul |
Abclonal |
20 ul |
EUR 183 |
Rabbit pAbPC5 Rabbit pAb |
A9997-50ul |
Abclonal |
50 ul |
EUR 223 |
Ttc39b 3'UTR Luciferase Stable Cell Line |
TU121312 |
ABM |
1.0 ml |
Ask for price |
TTC39B 3'UTR GFP Stable Cell Line |
TU077428 |
ABM |
1.0 ml |
EUR 1394 |
Ttc39b 3'UTR GFP Stable Cell Line |
TU171312 |
ABM |
1.0 ml |
Ask for price |
Ttc39b 3'UTR Luciferase Stable Cell Line |
TU222613 |
ABM |
1.0 ml |
Ask for price |
TTC39B 3'UTR Luciferase Stable Cell Line |
TU027428 |
ABM |
1.0 ml |
EUR 1394 |
Ttc39b 3'UTR GFP Stable Cell Line |
TU272613 |
ABM |
1.0 ml |
Ask for price |
TTC39B Protein Vector (Mouse) (pPB-C-His) |
PV242746 |
ABM |
500 ng |
EUR 603 |
TTC39B Protein Vector (Mouse) (pPB-N-His) |
PV242747 |
ABM |
500 ng |
EUR 603 |
TTC39B Protein Vector (Mouse) (pPM-C-HA) |
PV242748 |
ABM |
500 ng |
EUR 603 |
TTC39B Protein Vector (Mouse) (pPM-C-His) |
PV242749 |
ABM |
500 ng |
EUR 603 |
TTC39B Protein Vector (Rat) (pPB-C-His) |
PV313554 |
ABM |
500 ng |
EUR 603 |
TTC39B Protein Vector (Rat) (pPB-N-His) |
PV313555 |
ABM |
500 ng |
EUR 603 |
TTC39B Protein Vector (Rat) (pPM-C-HA) |
PV313556 |
ABM |
500 ng |
EUR 603 |
TTC39B Protein Vector (Rat) (pPM-C-His) |
PV313557 |
ABM |
500 ng |
EUR 603 |
Ttc39b sgRNA CRISPR Lentivector (Mouse) (Target 1) |
K4952202 |
ABM |
1.0 ug DNA |
EUR 154 |
Ttc39b sgRNA CRISPR Lentivector (Mouse) (Target 2) |
K4952203 |
ABM |
1.0 ug DNA |
EUR 154 |
Ttc39b sgRNA CRISPR Lentivector (Mouse) (Target 3) |
K4952204 |
ABM |
1.0 ug DNA |
EUR 154 |
Ttc39b sgRNA CRISPR Lentivector (Rat) (Target 1) |
K6591502 |
ABM |
1.0 ug DNA |
EUR 154 |
Ttc39b sgRNA CRISPR Lentivector (Rat) (Target 2) |
K6591503 |
ABM |
1.0 ug DNA |
EUR 154 |
Ttc39b sgRNA CRISPR Lentivector (Rat) (Target 3) |
K6591504 |
ABM |
1.0 ug DNA |
EUR 154 |
TTC39B Protein Vector (Human) (pPB-C-His) |
PV044437 |
ABM |
500 ng |
EUR 329 |
TTC39B Protein Vector (Human) (pPB-N-His) |
PV044438 |
ABM |
500 ng |
EUR 329 |
TTC39B Protein Vector (Human) (pPM-C-HA) |
PV044439 |
ABM |
500 ng |
EUR 329 |
TTC39B Protein Vector (Human) (pPM-C-His) |
PV044440 |
ABM |
500 ng |
EUR 329 |
TTC39B sgRNA CRISPR Lentivector (Human) (Target 1) |
K2551102 |
ABM |
1.0 ug DNA |
EUR 154 |
TTC39B sgRNA CRISPR Lentivector (Human) (Target 2) |
K2551103 |
ABM |
1.0 ug DNA |
EUR 154 |
TTC39B sgRNA CRISPR Lentivector (Human) (Target 3) |
K2551104 |
ABM |
1.0 ug DNA |
EUR 154 |
ACTB Rabbit pAb |
AC006 |
Abclonal |
50 ul |
EUR 176 |
TUBA4A Rabbit pAb |
AC007 |
Abclonal |
50 ul |
EUR 195 |
TUBA4A Rabbit pAb |
AC014 |
Abclonal |
50 ul |
EUR 223 |
GAPDH Rabbit pAb |
AC027 |
Abclonal |
50 ul |
EUR 176 |
TUBA4A Rabbit pAb |
AC031 |
Abclonal |
50 ul |
EUR 195 |
Tau Rabbit pAb |
A0002-100ul |
Abclonal |
100 ul |
EUR 308 |
Tau Rabbit pAb |
A0002-200ul |
Abclonal |
200 ul |
EUR 459 |
Tau Rabbit pAb |
A0002-20ul |
Abclonal |
20 ul |
EUR 183 |
Tau Rabbit pAb |
A0002-50ul |
Abclonal |
50 ul |
EUR 223 |
Rb Rabbit pAb |
A0003-100ul |
Abclonal |
100 ul |
EUR 308 |
Rb Rabbit pAb |
A0003-200ul |
Abclonal |
200 ul |
EUR 459 |
Rb Rabbit pAb |
A0003-20ul |
Abclonal |
20 ul |
EUR 183 |
Rb Rabbit pAb |
A0003-50ul |
Abclonal |
50 ul |
EUR 223 |
TLR4 Rabbit pAb |
A0007-100ul |
Abclonal |
100 ul |
EUR 308 |
TLR4 Rabbit pAb |
A0007-200ul |
Abclonal |
200 ul |
EUR 459 |
TLR4 Rabbit pAb |
A0007-20ul |
Abclonal |
20 ul |
EUR 183 |
TLR4 Rabbit pAb |
A0007-50ul |
Abclonal |
50 ul |
EUR 223 |
PARP1 Rabbit pAb |
A0010-100ul |
Abclonal |
100 ul |
EUR 459 |
PARP1 Rabbit pAb |
A0010-200ul |
Abclonal |
200 ul |
EUR 686 |
PARP1 Rabbit pAb |
A0010-20ul |
Abclonal |
20 ul |
EUR 183 |
PARP1 Rabbit pAb |
A0010-50ul |
Abclonal |
50 ul |
EUR 308 |
SNCA Rabbit pAb |
A0012-100ul |
Abclonal |
100 ul |
EUR 308 |
SNCA Rabbit pAb |
A0012-200ul |
Abclonal |
200 ul |
EUR 459 |
SNCA Rabbit pAb |
A0012-20ul |
Abclonal |
20 ul |
Ask for price |
SNCA Rabbit pAb |
A0012-50ul |
Abclonal |
50 ul |
Ask for price |
TYMS Rabbit pAb |
A0017-100ul |
Abclonal |
100 ul |
EUR 308 |
TYMS Rabbit pAb |
A0017-200ul |
Abclonal |
200 ul |
EUR 459 |
TYMS Rabbit pAb |
A0017-20ul |
Abclonal |
20 ul |
Ask for price |
TYMS Rabbit pAb |
A0017-50ul |
Abclonal |
50 ul |
Ask for price |
ENO2 Rabbit pAb |
A0022-100ul |
Abclonal |
100 ul |
EUR 308 |
ENO2 Rabbit pAb |
A0022-200ul |
Abclonal |
200 ul |
EUR 459 |
ENO2 Rabbit pAb |
A0022-20ul |
Abclonal |
20 ul |
Ask for price |
ENO2 Rabbit pAb |
A0022-50ul |
Abclonal |
50 ul |
Ask for price |
FAK Rabbit pAb |
A0024-100ul |
Abclonal |
100 ul |
EUR 384 |
FAK Rabbit pAb |
A0024-200ul |
Abclonal |
200 ul |
Ask for price |
FAK Rabbit pAb |
A0024-20ul |
Abclonal |
20 ul |
EUR 183 |
FAK Rabbit pAb |
A0024-50ul |
Abclonal |
50 ul |
EUR 265 |
STAT1 Rabbit pAb |
A0027-100ul |
Abclonal |
100 ul |
EUR 308 |
STAT1 Rabbit pAb |
A0027-200ul |
Abclonal |
200 ul |
EUR 459 |
STAT1 Rabbit pAb |
A0027-20ul |
Abclonal |
20 ul |
EUR 183 |
STAT1 Rabbit pAb |
A0027-50ul |
Abclonal |
50 ul |
EUR 223 |
TH Rabbit pAb |
A0028-100ul |
Abclonal |
100 ul |
EUR 308 |
TH Rabbit pAb |
A0028-200ul |
Abclonal |
200 ul |
EUR 459 |
TH Rabbit pAb |
A0028-20ul |
Abclonal |
20 ul |
EUR 183 |
TH Rabbit pAb |
A0028-50ul |
Abclonal |
50 ul |
EUR 223 |
TNFRSF1A Rabbit pAb |
A0033-100ul |
Abclonal |
100 ul |
EUR 308 |
TNFRSF1A Rabbit pAb |
A0033-200ul |
Abclonal |
200 ul |
EUR 459 |
TNFRSF1A Rabbit pAb |
A0033-20ul |
Abclonal |
20 ul |
EUR 183 |
TNFRSF1A Rabbit pAb |
A0033-50ul |
Abclonal |
50 ul |
EUR 223 |
BRAF Rabbit pAb |
A0038-100ul |
Abclonal |
100 ul |
EUR 308 |
BRAF Rabbit pAb |
A0038-200ul |
Abclonal |
200 ul |
EUR 459 |
BRAF Rabbit pAb |
A0038-20ul |
Abclonal |
20 ul |
EUR 183 |
BRAF Rabbit pAb |
A0038-50ul |
Abclonal |
50 ul |
EUR 223 |
GRB2 Rabbit pAb |
A0039-100ul |
Abclonal |
100 ul |
EUR 308 |
GRB2 Rabbit pAb |
A0039-200ul |
Abclonal |
200 ul |
EUR 459 |
GRB2 Rabbit pAb |
A0039-20ul |
Abclonal |
20 ul |
Ask for price |
GRB2 Rabbit pAb |
A0039-50ul |
Abclonal |
50 ul |
Ask for price |
MET Rabbit pAb |
A0040-100ul |
Abclonal |
100 ul |
EUR 308 |
MET Rabbit pAb |
A0040-200ul |
Abclonal |
200 ul |
EUR 459 |
MET Rabbit pAb |
A0040-20ul |
Abclonal |
20 ul |
EUR 183 |
MET Rabbit pAb |
A0040-50ul |
Abclonal |
50 ul |
EUR 223 |
CTSD Rabbit pAb |
A0041-100ul |
Abclonal |
100 ul |
EUR 308 |
CTSD Rabbit pAb |
A0041-200ul |
Abclonal |
200 ul |
EUR 459 |
CTSD Rabbit pAb |
A0041-20ul |
Abclonal |
20 ul |
Ask for price |
CTSD Rabbit pAb |
A0041-50ul |
Abclonal |
50 ul |
Ask for price |
FGFR2 Rabbit pAb |
A0044-100ul |
Abclonal |
100 ul |
EUR 308 |
FGFR2 Rabbit pAb |
A0044-200ul |
Abclonal |
200 ul |
EUR 459 |
PSMB1 Rabbit pAb |
A1043-100ul |
Abclonal |
100 ul |
EUR 308 |
PSMB1 Rabbit pAb |
A1043-200ul |
Abclonal |
200 ul |
EUR 459 |
PSMB1 Rabbit pAb |
A1043-20ul |
Abclonal |
20 ul |
EUR 183 |
PSMB1 Rabbit pAb |
A1043-50ul |
Abclonal |
50 ul |
EUR 223 |
RFTN1 Rabbit pAb |
A10430-100ul |
Abclonal |
100 ul |
EUR 308 |
RFTN1 Rabbit pAb |
A10430-200ul |
Abclonal |
200 ul |
EUR 459 |
RFTN1 Rabbit pAb |
A10430-20ul |
Abclonal |
20 ul |
EUR 183 |
RFTN1 Rabbit pAb |
A10430-50ul |
Abclonal |
50 ul |
EUR 223 |
SEMA4F Rabbit pAb |
A10432-100ul |
Abclonal |
100 ul |
EUR 308 |
SEMA4F Rabbit pAb |
A10432-200ul |
Abclonal |
200 ul |
EUR 459 |
SEMA4F Rabbit pAb |
A10432-20ul |
Abclonal |
20 ul |
EUR 183 |
SEMA4F Rabbit pAb |
A10432-50ul |
Abclonal |
50 ul |
EUR 223 |
SLC16A10 Rabbit pAb |
A10433-100ul |
Abclonal |
100 ul |
EUR 308 |
SLC16A10 Rabbit pAb |
A10433-200ul |
Abclonal |
200 ul |
EUR 459 |
SLC16A10 Rabbit pAb |
A10433-20ul |
Abclonal |
20 ul |
EUR 183 |
SLC16A10 Rabbit pAb |
A10433-50ul |
Abclonal |
50 ul |
EUR 223 |
SLC22A9 Rabbit pAb |
A10434-100ul |
Abclonal |
100 ul |
EUR 308 |
SLC22A9 Rabbit pAb |
A10434-200ul |
Abclonal |
200 ul |
EUR 459 |
SLC22A9 Rabbit pAb |
A10434-20ul |
Abclonal |
20 ul |
EUR 183 |
SLC22A9 Rabbit pAb |
A10434-50ul |
Abclonal |
50 ul |
EUR 223 |
SLC44A4 Rabbit pAb |
A10435-100ul |
Abclonal |
100 ul |
EUR 308 |
SLC44A4 Rabbit pAb |
A10435-200ul |
Abclonal |
200 ul |
EUR 459 |
SLC44A4 Rabbit pAb |
A10435-20ul |
Abclonal |
20 ul |
EUR 183 |
SLC44A4 Rabbit pAb |
A10435-50ul |
Abclonal |
50 ul |
EUR 223 |
SLC4A5 Rabbit pAb |
A10436-100ul |
Abclonal |
100 ul |
EUR 308 |
SLC4A5 Rabbit pAb |
A10436-200ul |
Abclonal |
200 ul |
EUR 459 |
SLC4A5 Rabbit pAb |
A10436-20ul |
Abclonal |
20 ul |
EUR 183 |
Macular structural characteristics on the limits and outside the lesions include intrarinal hyperreflective points, macular sistoid edema, subretinal fluid and loss of ellipsoid zone (EZ). Selective EZ losses found in 6 of 12 eyes showed recovery in 4 eyes after receiving anti-virus treatment. In the eye of CMVR, there are microvascular abnormalities and microstructure in the macular area without cmvr lesions that are clinically seen. Our results provide interesting insights into Retina CMV infection.